STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS
Stopped early · Phase 2
Conditions studied: Myelodysplastic Syndrome (MDS)
In brief
The main objective of this study was to assess the safety profile of MBG453 (sabatolimab) in combination with FDA approved hypomethylating agents (HMAs) of investigator's choice (IV Decitabine or Azacitidine /SC Azacitidine /Oral Decitabine (cedazuridine combination (INQOVI))).
Key facts
- Study ID
- NCT04878432
- Run by
- Novartis Pharmaceuticals
- People needed
- 39
- Starts
- 2022-03-17
- Expected to finish
- 2024-09-01
- Last updated by the study team
- 2025-10-16
Who can join
Age: 18 and older, up to 99. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Mayo Clinic Arizona — Phoenix, Arizona, United States
- Arizona Oncology Associates — Tucson, Arizona, United States
- SCRI-Colorado Blood Cancer Institute — Denver, Colorado, United States
- Yale University School Of Medicine — New Haven, Connecticut, United States
- Advent Health Orlando — Orlando, Florida, United States
- Uni of Massachusetts Medical Center — Worcester, Massachusetts, United States
- University Of Michigan — Ann Arbor, Michigan, United States
- Karmanos Cancer Institute — Detroit, Michigan, United States
- Tisch Hospital NYU Langone — New York, New York, United States
- Mount Sinai Medical Center — New York, New York, United States
- Duke Cancer Institute — Durham, North Carolina, United States
- University Hospitals Of Cleveland — Cleveland, Ohio, United States
- Cleveland Clinic — Cleveland, Ohio, United States
- Uni Of TX MD Anderson Cancer Cntr — Houston, Texas, United States
- Texas Oncology San Antonio USO — San Antonio, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.